Supplemental Tables 1-5, Figures 1-2 from Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

Abstract

<p>Supplemental Tables 1-5, Figures 1-2. Supplemental Table I: Topotecan in vitro activity in the presence and absence of talazoparib (10 nM) Supplemental Table II. Efficacy of PPTP Single agents and combinations in Xenograft Models Supplemental Table III. Efficacy of Combination B against PPTP Xenograft Models Supplemental Table IV: Therapeutic Enhancement in vivo. Supplemental Table V. Responses to Tumor Models to Combination B (talazoparib plus low-dose temozolomide) Supplemental Figure 1. Kaplan-Meier estimates for Event-Free Survival in Ewing sarcoma xenograft models. Supplemental Figure 2. Quantification of total (cleaved + uncleaved) PARP, and cleaved PARP following 5 days treatment of TC-71R tumors with talazoparib, temozolomide or the combination. Relative levels of total and cleaved PARP are shown for parental TC-71 xenografts.</p>